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Objective: The purpose of this study was to determine the prevalence of adverse drug reactions 
(ADRs) reported in emergency departments (EDs) and carry out a thorough characterization 
of these to assess preventability, seriousness that required hospitalization, subsequent 30-day 
mortality, and economic burden.
Methods: This was a retrospective cohort study of data from an active pharmacovigilance 
project at 32 EDs in the Lombardy region collected between January 1, 2010 and December 31, 
2011. Demographic, clinical, and pharmacological data on patients admitted to EDs were 
collected by trained and qualified monitors, and deterministic record linkage was performed 
to estimate hospitalizations. Pharmacoeconomic analyses were based on Diagnosis-Related 
Group reimbursement.
Results: 8,862 ADRs collected with an overall prevalence rate of 3.5 per 1,000 visits. Of 
all ADRs, 42% were probably/definitely preventable and 46.4% were serious, 15% required 
hospitalization, and 1.5% resulted in death. The System Organ Classes most frequently associ-
ated with ADRs were: skin and subcutaneous tissue, gastrointestinal, respiratory thoracic and 
mediastinal, and nervous system disorders. The most common Anatomical Therapeutic Chemical 
classes involved in admissions were J (anti-infectives and immunomodulating agents), B (blood 
and blood-forming organs), and N (nervous system). Older age, yellow and red triage, higher 
number of concomitantly taken drugs, and previous attendance in ED for the same ADR were 
significantly associated with an increased risk of hospitalization. The total cost associated with 
ADR management was €5,184,270, with a mean cost per patient of €585. Fifty-eight percent 
of the economic burden was defined as probably/definitely preventable.
Conclusion: ADRs are a serious health/economic issue in EDs. This assessment provides a 
thorough estimation of their seriousness, preventability, and burden impact in a large population 
from a representative European region.
Keywords: adverse drug reaction, preventability, economic impact, emergency department, 
pharmacovigilance
Introduction
Adverse drug reactions (ADRs) are a leading cause of mortality and morbidity in health 
care and a significant burden on health care resources.1,2 Estimates of the prevalence of 
ADRs in the literature vary depending on the definition of ADR used, the study setting, 
and the study population.3 In addition, the incidence of ADR-related admissions may 
be underestimated due to lack of documentation in patient medical notes,4–6 on average 
being 0.1%–54% of all hospital admissions. ADRs are a significant cause of emergency 
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department (ED) visits,7,8 and many are preventable, eg, due 
to drug treatment, lack thereof, or therapies inconsistent with 
current best practice.9,10 EDs are ideal places to study ADRs 
because they are an essential part of health care system, 
serve as an interface between hospitals and communities, and 
constitute the most important source of information about the 
incidence, seriousness, and costs of ADRs.11–13
Previous studies of ED visits associated with ADRs 
have been limited to one hospital setting,14–16 a specific 
population,17–21 specific classes of drug22,23 or types of 
ADRs,24,25 a retrospective study design,26,27 short periods 
of observation,13,28–32 or did not provide information on 
 preventability.33–35 More extensive studies of ED visits for 
outpatient ADRs are thus crucial and needed. We have deter-
mined the prevalence, preventability, seriousness requiring 
hospitalization, subsequent 30-day mortality, and economic 
impact of ADRs presenting to multiple EDs serving a large 
proportion of the Lombardy region over a 2-year period.
Materials and methods
setting
This was a retrospective cohort analysis based on ADR charts 
collected between January 1, 2010 and December 31, 2011 
as part of the prospective active pharmacovigilance project 
Monitoring of ADRs in ED (MEREAFaPS) that is collect-
ing ADRs reported in EDs. The study involves 32 EDs in 
16 general hospitals serving different catchment areas of 
Lombardy, the largest region in Italy with a population of 
almost 10 million, and altogether accounts for 37.9% of ED 
visits in the region in the study period. All ADRs reported 
from patients having at least one suspected ADR, except for 
those from vaccines, were included in the analysis. Patients 
who developed an ADR while in the ED for any other reason 
were included. The local institutional ethics committee of 
the coordinating center, Niguarda Ca’ Granda Hospital, was 
informed of the study according to the legal requirements 
concerning observational studies.
Data source
For this study we used two sources of data, ie, ADRs in ED 
data collected prospectively as part of the MEREAFaPS 
project and hospitalization data from the hospital discharge 
database.
The physicians in each ED were informed about the aims 
of the MEREAFaPS study, and a monitor was assigned for 
each hospital. The monitors were medical doctors, pharma-
cists, and biologists, and underwent an intensive course on 
the theoretical and practical aspects of pharmacovigilance 
in an ED. For each ADR notified, the following information 
were recorded: demographic characteristics (age, gender, 
ethnic group, deduced from the place of birth if not otherwise 
indicated); patient clinical status on ED visits; triage code; 
ongoing therapy, (suspected and concomitant drugs, route, 
duration, and dosage) codified according to the Anatomical 
Therapeutic Chemical (ATC) classification system and thera-
peutic indication for the suspected drug; a description of the 
ADR according to diagnosis and symptoms, codified as 
detailed by the Medical Dictionary for Regulatory Activities 
(MedDRA) dictionary and organized by System Organ Class 
(SOC)15 and its degree of seriousness, classified according to 
the World Health Organization criteria as fatal, life-threatening, 
or requiring hospitalization of the patient, or causing serious/
permanent disability;36 history of previous presentation to an 
ED for the same ADR; and preventability. The diagnosis of 
ADR and investigation of the relationship between develop-
ment of the ADR and the drug used were always done by the 
ED physicians in collaboration with the monitor.
The hospitalization database contains the following 
information: demographic characteristics (age, sex), 30-day 
mortality, and Diagnosis-Related Group (DRG) reimburse-
ment rate. To estimate which of the ADRs observed at ED 
admission or during ED stay led to hospitalization, we per-
formed a deterministic linkage between two data sources 
using the unique ID anonymous patient code existing in 
both databases.
Outcome measure
The primary outcome of the study was to determine the rate 
of ADRs presenting in ED, regardless of whether the ADR 
was a reason for the visit. In accordance with new European 
Medicine Agency legislation, diagnosis of an ADR is based 
on the following definition: a response to a medicinal product 
that is noxious and unintended, arising from use of a medicinal 
product within the terms of the marketing authorization as well 
as from use outside the terms of the marketing authorization, 
including overdose, misuse, abuse and medication errors, 
and suspected adverse reactions associated with occupational 
exposure.37 The causality assessment was done using the 
Naranjo algorithm.38 Each ADR was characterized in terms 
of the SOC and ATC classes most frequently involved. We 
also assessed ADR preventability (defined as definitely or 
probably preventable, or not  preventable), using the criteria 
devised by Schumock and Thornton.39,40 We evaluated seri-
ousness, estimated potential predictors of ADRs requiring 
hospitalization using a multivariate model, and analyzed 
30-day mortality. In this group, only patients who died during 
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 hospitalization or within the 30 days  following hospital dis-
charge were considered. Finally, we estimated the economic 
burden of ADR-related ED visits by calculating direct medical 
costs in two stages. Stage 1 included the average cost of an 
ED visit at each hospital, and stage 2 included costs related 
to patient hospitalization following an ADR, calculated from 
the DRG reimbursement present in the hospitalization data. 
Costs are reported in euros.
statistical analysis
Descriptive statistics are shown as frequencies and per-
centages for categorical data and as means with standard 
deviations for continuous data. We used univariate and mul-
tivariate logistic regression to estimate the odds ratios (ORs) 
with 95% confidence intervals (CIs) of potential predictors 
of hospitalization among total ADRs. Economic estimates of 
cost are presented as means with standard deviations (SD).
All results were considered to be statistically significant 
at P,0.05. Data management and statistical analysis were 
carried out using SAS version 9.2 software (SAS Institute, 
Cary, NC, USA).
Results
In the 2-year study period, a total of 2,561,400 ED visits were 
made, of which 8,862 were ADR-related, with an overall 
prevalence rate of 3.5 per 1,000 ED visits (Figure 1). The 
characteristics of patients with ADRs are reported in Table 1. 
Patients with an ADR had a mean (± SD) age of 55.9±24.3 years, 
most are female and European, and more than half received 
two or more drugs at the time of their ED visit (Table 1). There 
were 4,111 serious ADRs (46.4%), and among these 1,332 
(15% of total ADRs) led to  hospitalization. The fatality rate 
for all ADRs reported in the ED was 1.5%.
Most patients with a serious ADR were taking more 
than one drug (64%) compared with overall ADR (54.3%); 
similarly, the amount of polypharmacy increased with the 
degree of seriousness, being 77.9% in patients hospitalized 
following ADR in ED and 82.2% in patients who died within 
30 days of discharge.
Preventable ADRs, a definition which includes both the 
“definitely” and “probably” preventable ADRs, were in total 
42%; of these 51.6% were serious, 59.6% were hospitalized, 
and 61.2% died.
SOCs most frequently associated with ADRs of sig-
nif icant severity were: skin and subcutaneous tissue, 
followed by gastrointestinal, respiratory thoracic and 
mediastinal, and nervous system disorders (Table 2). The 
ATC classes most commonly involved in admissions 
(Table 3) were J (anti-infectives for systemic use), B (blood 
and blood-forming organs), and N (nervous system). In 
terms of seriousness of ADRs, the ATC class most often 
involved was V (various), followed by A (alimentary tract 
and metabolism) and C (cardiovascular).
The most commonly involved drugs (see Table 4) were 
acetylsalicylic acid (34.5% being preventable), amoxicillin/
clavulanic (32.1% preventable), and warfarin (48.6% pre-
ventable). The most frequent suspect drugs in serious ADRs 
and in inpatients who died within 30 days after discharge are 
reported in Table S1.
With regard to multivariate predictors of hospitalization, 
older age (OR 2.76, 95% CI 2.38–3.2), male sex (OR 1.2, 
95% CI 1.06–1.37), yellow and red triage (OR 3.62, 95% CI 
3.18–4.12), increasing number of concomitant drugs taken 
(from OR 1.81, 95% CI 1.54–2.13 in patients  taking 2–4 drugs, 
to OR 5.5, 95% CI 3.65–8.29 in those taking $10 drugs) and 
previous attendance in ED for the same ADR (OR 2.04, 
95% CI 1.45–2.88) were associated with a significantly 
increased risk of hospitalization (Table 5).
The total cost incurred by the National Health Service 
because of ADR-related ED visits and subsequent hospi-
talizations in MEREAFaPS hospitals for the 2010–2011 
period was estimated to be €5,184,270, with an average cost 
of €585±2,149 per patient (Table 6). The average estimated 
2,561,400 ED visits in MEREAFaPS hospitals, between 2010 and 2011
8,983 ED visits ADR-related (3.5 per 1,000 ED visits) in MEREAFaPS
hospitals, between 2010 and 2011
8,862 ED visits ADR-related (3.5 per 1,000 ED visits) in MEREAFaPS
hospitals, between 2010 and 2011, excluding those from vaccines
4,751 (53.6%) not serious
ADRs
129 inpatients died within
 30 days after discharge
1,332 patients hospitalized
following ADRs in ED
4,111 (46.4%) serious* ADRs
in ED
Figure 1 Flow chart of selection criteria of adverse drug reactions in emergency 
department and outcomes of interests, MEREaFaPs hospitals, 2010–2011.
Note: *aDR that was fatal, life-threatening, required hospitalization of the patient, 
or caused serious/permanent disability.
Abbreviations: aDR, adverse drug reaction; ED, emergency department; MEREaFaPs, 
Monitoring of aDRs in ED.
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Table 1 Characteristics of patients with adverse drug reactions in emergency departments at MEREaFaPs hospitals, 2010–2011
Patient characteristics ADRs in ED 
(n=8,862)
Serious  
ADRs* in ED 
(n=4,111)
Patients hospitalized  
following ADRs in ED  
(n=1,332)
Inpatients died within 
30 days after discharge 
(n=129)
n (%) n (%) n (%) n (%)
age, years
 ,65 4,932 (55.7) 1,903 (46.3) 358 (26.9) 5 (3.9)
 $65 3,930 (44.3) 2,208 (53.7) 974 (73.1) 124 (96.1)
Mean ± sD age, years 55.9±24.3 62.0±21.6 70.7±(18.1) 81.8±9
sex
 Female 4,936 (55.7) 2,265 (55.1) 678 (50.9) 64 (49.6)
 Male 3,926 (44.3) 1,846 (44.9) 654 (49.1) 65 (50.4)
Ethnic group
 Others 420 (4.7) 134 (3.3) 22 (1.7) 0 (0)
 European 8,442 (95.3) 3,977 (96.7) 1,310 (98.3) 129 (100)
Triage
 Missing 171 (1.9) 87 (2.1) 16 (1.2) 0 (0)
 g + W 6,435 (72.6) 2,323 (56.5) 619 (46.5) 37 (28.7)
 R + Y 2,256 (25.5) 1,701 (41.4) 697 (52.3) 92 (71.3)
Concomitant drugs (n)
 1 4,053 (45.7) 1,482 (36) 294 (22.1) 23 (17.8)
 2–4 3,446 (38.9) 1,721 (41.9) 558 (41.9) 48 (37.2)
 5–9 1,245 (14) 822 (20) 424 (31.8) 50 (38.8)
 11+ 118 (1.3) 86 (2.1) 56 (4.2) 8 (6.2)
Previous ED access for same aDR
 no 8,636 (97.4) 3,996 (97.2) 1,277 (95.9) 127 (98.4)
 Yes 226 (2.6) 115 (2.8) 55 (4.1) 2 (1.6)
Preventability
 not preventable 5,137 (58) 1,989 (48.4) 538 (40.4) 50 (38.8)
  Probably/definitely preventable 3,725 (42) 2,122 (51.6) 794 (59.6) 79 (61.2)
Note: *aDR that was fatal, life-threatening, requiring hospitalization of the patient, or that caused serious/permanent disability.
Abbreviations: aDR, adverse drug reaction; ED, emergency department; g + W, green and white triage; MEREaFaPs, Monitoring of aDRs in ED; R + Y, red and yellow 
triage; sD, standard deviation.
Table 2 Distribution of adverse drug reactions in emergency 
departments at MEREaFaPs hospitals, 2010–2011, according to 
first ten SOC classifications
SOC name n (%a) Serious (%b per 
each SOC)
skin and subcutaneous tissue disorders 3,241 (26.6) 35.8
gastrointestinal disorders 1,899 (15.6) 53.0
Respiratory, thoracic and mediastinal  
disorders
1,245 (10.2) 42.3
nervous system disorders 1,244 (10.2) 63.6
general disorders and administration  
site conditions
878 (7.2) 45.0
Metabolism and nutrition disorders 589 (4.8) 78.1
Vascular disorders 468 (3.8) 53.6
Psychiatric disorders 445 (3.6) 66.3
Cardiac disorders 319 (2.6) 59.6
Renal and urinary disorders 272 (2.2) 64.7
all others 1,595 (13.1) –
Notes: aColumn percentage; brow percentage.
Abbreviations: MEREaFaPs, Monitoring of aDRs in ED; sOC, system Organ Class.
Table 3 Distribution of adverse drug reactions in emergency 
departments at MEREaFaPs hospitals, 2010–2011, according to 
aTC level 1
Therapeutic category  
(level 1 ATC)
n (%a) Serious (%b per 
each ATC)
J. anti-infectives for systemic use 2,333 (21.0) 36.1
B. Blood and blood-forming organs 2,028 (18.3) 52.4
n. nervous system 1,943 (17.5) 53.8
C. Cardiovascular system 1,445 (13.0) 62.7
M. Musculoskeletal system 1,367 (12.3) 41.6
a.  alimentary tract and metabolism 986 (8.9) 67.7
R. Respiratory system 254 (2.3) 28.0
l.  antineoplastic and 
immunomodulating agents
177 (1.6) 59.3
g.  genitourinary system  
and sex hormones
146 (1.3) 31.5
h.  systemic hormonal  
preparations excluding sex  
hormones and insulins
142 (1.3) 45.8
s. sensory organs 79 (0.7) 7.6
D. Dermatologicals 78 (0.7) 14.1
V. Various 76 (0.7) 68.4
P.  antiparasitic products  
insecticides and repellents
31 (0.3) 29.0
Notes: aColumn percentage; brow percentage.
Abbreviations: ATC, Anatomical Therapeutic Chemical classification; MEREAFaPS, 
Monitoring of aDRs in ED.
cost was €1,166±3,054 to treat patients with serious ADRs, 
€3,422±4,613 for ED visits leading to hospitalization, and 
€4,147±3,789 in ADRs that proved fatal. The proportion of 
preventable cases identified in this study indicates a potential 
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Table 4 Ten most frequent suspect drugs for aDRs in ED and 
patients hospitalized following aDRs in EDs at MEREaFaPs 
hospitals, 2010–2011
n Probably/definitely 
preventable (%)
ADRs in ED (n=8,862)
acetylsalicylic acid 936 323 (34.5)
amoxicillin-clavulanate 878 282 (32.1)
Warfarin 731 355 (48.6)
amoxicillin 479 186 (38.8)
insulins and analogs 377 250 (66.3)
Ketoprofen 353 153 (43.3)
ibuprofen 245 95 (38.8)
Diclofenac 193 96 (49.7)
acetaminophen 182 54 (29.7)
Levofloxacin 172 55 (32)
Patients hospitalized following ADRs in ED (n=1,332)
Warfarin 263 150 (57)
acetylsalicylic acid 215 118 (54.9)
insulins and analogs 77 61 (79.2)
acenocoumarol 51 26 (51)
Ticlopidine 51 37 (72.5)
Furosemide 47 33 (70.2)
amoxicillin-clavulanate 40 15 (37.5)
Metformin 40 30 (75)
Digoxin 28 17 (60.7)
Enalapril 28 15 (53.6)
Abbreviations: aDR, adverse drug reaction; ED, emergency department; 
MEREaFaPs, Monitoring of aDRs in ED.
Table 5 Factors associated with hospitalizations for patients with 8,862 adverse drug reactions in emergency department at MEREaFaPs 
hospitals, 2010–2011
OR (95% CI) P-value AOR (95% CI) P-value
$65 versus ,65 years 4.21 (3.7–4.79) ,0.001 2.76 (2.38–3.2) ,0.001*
Male versus female 1.26 (1.12–1.41) ,0.001 1.2 (1.06–1.37) 0.002*
European ethnicity versus other 3.32 (2.15–5.12) 0.136 1.41 (0.9–2.22) 0.136
Triage yellow/red versus white/green 4.2 (3.72–4.75) ,0.001 3.62 (3.18–4.12) ,0.001*
Concomitant drugs (n) versus 1 as reference
 2–4 2.47 (2.13–2.87) ,0.001 1.81 (1.54–2.13) ,0.001*
 5–9 6.6 (5.59–7.8) ,0.001 3.39 (2.81–4.09) ,0.001*
 10+ 11.55 (7.9–16.9) ,0.001 5.5 (3.65–8.29) ,0.001*
Previous ED access for same aDR 1.85 (1.36–2.53) ,0.001 2.04 (1.45–2.88) ,0.001*
Note: *Statistically significant in the multivariate model.
Abbreviations: ADR, adverse drug reaction; ED, emergency department; OR, odds ratio; CI, confidence interval; AOR, odds ratio adjusted for all variables in the table.
saving of €3,009,800 for the National Health Service, repre-
senting 58% of the total expenses incurred in the treatment 
of ADRs in the ED.
Discussion
Our study is the first to contribute useful information on the 
clinical and economic impact of ADRs in Italy via a long-term 
survey of several EDs that included a substantial number of 
patients over a 2-year period. Ours is also one of the largest 
such studies. We present a clear picture, reporting on the 
prevalence, seriousness, and preventability of drug-related 
visits to the ED and their real economic impact over a long 
period in a large number of EDs. Previous studies addressing 
the issue of ADRs in the ED were limited to either single 
hospitals with small numbers of patients, or to short periods 
of observation or a specific population without insight into 
clinical or economic impact.14,29,31,34,35,41 They also differ in the 
criteria used to identify ADR, collection periods, and study 
design.28,42,43 Therefore, data from these studies cannot be 
extrapolated reliably to a general population.
In our study, the prevalence of ADR-related ED visits 
was less than 1%, as already reported for France.44 However, 
this value is strikingly different from that observed in other 
studies.14,26,42,43 The difference may be due in part to the dif-
ferent ADR inclusion criteria used in the various studies, 
ie, reported to EDs versus identified in ED or leading to ED 
visits, and/or due to the known dissimilarity in the incidence 
of medication-related ED visits between prospective and 
retrospective studies.42,29,43
Wiffen et al45 observed that patients in their ADR group 
were prescribed more drugs on average than those in the 
non-ADR group, a situation known to be associated with 
an increased prevalence of ADRs.43,46 In accordance with 
these data, our study shows a correlation between the risk 
of a serious ADR and the number of drugs being taken; 
regarding the effect of risk factors on the incidence of ADR-
related hospitalization, multiple regression analysis showed 
a statistically significant association between use of a large 
number of medications and the risk of presenting with an 
ADR that would require hospitalization. Likewise, we add 
further information on the issue of polypharmacy as a cause 
of ADRs; previous studies were only in elderly people, where 
polypharmacy is common, and showed that polypharmacy is a 
reliable predictor of rehospitalization and a prolonged length 
of hospital stay during which at least one ADR occurred.47
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Table 6 Cost of illness associated with aDRs in EDs at 
MEREaFaPs hospitals, 2010–2011
Cost (mean ± SD) Total cost
aDRs in ED (n=8,862) 585±2,149 5,184,270
serious* aDRs in ED (n=4,111) 1,166±3,054 4,793,426
Patients hospitalized following  
aDRs in ED (n=1,332)
3,422±4,613 4,558,104
inpatients died within 30 days  
after discharge (n=129)
4,147±3,789 534,963
not preventable (n=5,137) 423±1,751 2,172,951
Probably/definitely  
preventable (n=3,725)
808±2,584 3,009,800
Notes: Data are shown as the mean, standard deviation, and total cost in Euros. 
*aDR that was fatal, life-threatening, requiring hospitalization of the patient, or that 
caused serious/permanent disability.
Abbreviations: aDR, adverse drug reaction; ED, emergency department; 
sD, standard deviation.
Consistent with previous work,48–51 we found a high rate 
of preventability of ADRs requiring hospitalization and those 
resulting in death at 30 days. Reasons for such high rates may 
include errors in prescribing and/or monitoring, or poor com-
pliance, underscoring the importance of developing strategies 
to improve the quality and safety of prescribing.
Among the various drug classes that are particularly 
worthy of attention in terms of preventable ADRs are the 
classical anticoagulants. We observed that most of the 
patients who died within 30 days of discharge had suffered 
from anticoagulant-associated ADRs, 40.3% of which 
were attributable to warfarin. This evidence is consistent 
with the findings of previous studies indicating that antico-
agulants are among the drugs that need to be more closely 
monitored because of their propensity to lead to preventable 
hospitalizations.4,11,52
We found that several organ systems were affected by 
ADRs, with the highest frequency in the dermatological 
system, which is consistent with previous reports in the 
literature.13,44 Likewise, our results in terms of therapeutic 
categories more frequently involved in ADR (antibiotics, 
anticoagulants, digoxin, diuretics, hypoglycemic agents, and 
nonsteroidal anti-inflammatory drugs) are not dissimilar from 
those in the literature.53
Another aspect of this study is the estimate of the eco-
nomic impact associated with ADRs, information not yet 
available on ADRs observed in EDs and in such a large popu-
lation.54 Calculation of the impact of ADRs on costs is indeed 
complex.55 ADRs may increase costs because of increased 
likelihood of hospitalization, prolongation of hospital stay, 
and the additional clinical investigations needed in more seri-
ous cases. Further, ADRs may trigger prescription cascade 
when new medications are prescribed for conditions that are 
a consequence of another medication, conditions which are 
often an unrecognized ADR.56–58 This may explain in part 
why our analysis in an Italian setting estimated the costs for 
treatment of serious ADRs to be significantly higher than 
those observed in France, ie, €3,422 versus approximately 
€2,500, respectively.59
Studies carried out in general hospitals or specialist units 
suggest that the cost of an ADR depends on the nature of 
both the ADR and the culprit drug, and this has to be taken 
into account when designing programs to control costs and 
minimize ADRs.10,16 Our economic analysis highlights two 
relevant issues. The first is that ATC class A is associated with 
a high number of serious ADRs, and about 20% of the drugs 
dispensed were to treat diabetes. Antidiabetic drugs (ATC 
code A10) typically require periodic monitoring, and our data 
strengthen previous evidence of a progressive and significant 
increase in health care costs for patients in whom diabetes is 
not properly monitored.60 The second issue relates to prevent-
ability of ADRs. Our data show that 42% of reported ADRs 
were preventable, indicating a total cost-saving potential of 
€3 million, representing 58% of the total economic impact of 
ADRs. Likewise, a study in Germany showed the total cost 
of treating ADRs to be €434 million per year; considering 
the proportion of preventable cases (20.1%), this represented 
a potential cost saving of €87 million per year.61 Certain 
strategies are known to reduce the impact of ADRs, such 
as improving adherence to therapeutic guidelines, educa-
tional programs, identification of risk groups, and associate 
therapeutic drug monitoring, whenever available, to the 
evaluation of reliable biomarkers of safety and efficacy.16,62–64 
The heavy burden of preventable ADRs may translate into 
potentially significant cost savings if these strategies can be 
implemented further. In this respect, cooperation should be 
encouraged between clinicians, clinical pharmacologists, and 
pharmacists, who may play a significant role in preventing 
and decreasing the burden of ADRs.65
limits and strengths
This study was of a retrospective nature, so may have under-
estimated the prevalence of drug-related ED visits as a result 
of missing or inaccurately documented information. Indeed, 
retrospective studies cannot identify all reported ADR-related 
ED visits due to the limitations of the ICD codes used, which 
do not cover all illnesses potentially caused by ADRs. To 
address this limitation, we included only cases that were rec-
ognized and documented by emergency physicians as ADRs. 
Another limitation is that the ADRs in MEREAFaPS are the 
results of spontaneous reports of ADRs. The real prevalence 
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of ADRs is not known and a control group (with no ADRs) 
was not available; and this is also a limitation with regard to 
assessment of causality between ADRs and hospitalization. 
The DRG in Lombardy reflects reimbursement of hospitals 
by the National Health Service and not the actual costs 
incurred, although is designed to represent actual costs as 
far as possible. We could not extract from the DRG those 
costs associated with management of conditions not strictly 
related to the ADR.
This study has some important strengths. For example, 
we used computerized monitoring programs and trained 
professionals to detect ADRs, and physicians working in EDs 
to identify ADRs. In addition, this is the first retrospective 
analysis within a prospective study evaluating the reporting 
of ADRs in a large number of EDs over a long period. Fur-
ther, the study recorded mortality occurring up to 30 days 
after discharge. This is recognized as a good patient outcome 
indicator,66 although we cannot exclude as a confounding 
factor the possibility that mortality in some cases was due 
to other reasons. Moreover, this is the first study assessing 
hospitalization-related ADR costs in terms of seriousness and 
preventability, making it possible to estimate the potential 
cost savings in relation to the preventable cases observed.
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Supplementary materials
Table S1 Ten most frequent suspect drugs in: serious* aDRs 
in ED at MEREaFaPs hospitals, 2010–2011 and in inpatients who 
died within 30 days after discharge
n Probably/definitely 
preventable (%)
Serious* ADRs in ED (n=4,111)
acetylsalicylic acid 437 190 (43.5)
Warfarin 420 234 (55.7)
insulins and analogs 312 209 (67)
amoxicillin-clavulanate 311 131 (42.1)
amoxicillin 169 66 (39.1)
Ketoprofen 134 76 (56.7)
ibuprofen 99 44 (44.4)
Furosemide 90 56 (62.2)
Ticlopidine 80 47 (58.8)
Diclofenac 75 48 (64)
Inpatients died within 30 days after discharge (n=129)
Warfarin 52 31 (59.6)
acetylsalicylic acid 18 13 (72.2)
Ticlopidine 11 8 (72.7)
Furosemide 7 4 (57.1)
spironolactone 4 3 (75)
acenocoumarol 3 2 (66.7)
allopurinol 3 1 (33.3)
amiloride hydrochlorothiazide 3 2 (66.7)
Clopidogrel 3 0 (0)
Ceftriaxone 3 2 (66.7)
Note: *aDR that was fatal, life-threatening, requiring hospitalization of the patient, 
or caused serious/permanent disability.
Abbreviations: aDR, adverse drug reaction; ED, emergency department; MEREaFaPs, 
Monitoring of aDRs in ED.
